Subtitle
Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020.
Subtitle
Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020.
Proto therapy Time
July 2022
Executive summary
Data of 140 dosimetry studies was analyzed. In the 105 non-SABR studies, the average MHD was similar between IMRT and 3DCRT (10.9 Gy versus 10.6 Gy) and lower with particle beam therapy (proton 7.0 Gy; carbon-ion 1.9 Gy). Active respiratory motion management reduced exposure (7.4 Gy versus 9.3 Gy). In the SABR 35 studies, MHD was 4.0 Gy (0.0-32.4). MHD was lowest for carbon ions (0.5 Gy) compared to other techniques. Active respiratory motion management reduced exposure (2.4 Gy versus 5.0 Gy).
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
April 2024
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
Proton Therapy Publication
November 2023
Proton Therapy Mediates Dose Reductions to Brain Structures Associated with Cognition in Children with Medulloblastoma.
Proton Therapy Publication
October 2023
Radiation-induced skin and heart toxicity in patients with breast cancer treated with adjuvant proton radiotherapy: a comparison with photon radiotherapy.
Proton Therapy Publication
September 2023
Ultra-High Dose-Rate Proton FLASH Improves Tumor Control.
Proton Therapy Publication
June 2023
The current status of FLASH particle therapy: a systematic review.
Proton Therapy Publication
May and June 2023
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
April 2023
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.